Comparison of Ondansetron with Metoclopramide in the Control of Emesis Induced by Moderately Emetogenic Chemotherapy Used for Lymphoma and Leukaemia ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1994-08

AUTHORS

Edmond K. W. Chiu, Raymond Liang, Albert Lie, David Todd, T. K. Chan

ABSTRACT

Ondansetron was compared with conventional-dose metoclopramide in a randomised trial for emesis control in 56 patients with lymphoma and leukaemia receiving commonly used chemotherapeutic regimens that are moderately emetogenic. Emetogenic chemotherapeutic agents were administered on day 1 to lymphoma patients and on days 1 to 5 to leukaemia patients. Ondansetron was superior to metoclopramide in the complete control of acute emesis (75 vs 43%, p = 0.03). Control of delayed emesis in lymphoma patients was marginally better with ondansetron on days 2 (89 vs 64%, p = 0.140) and 3 (94 vs 68%, p = 0.054). Continuous control of emesis for leukaemia patients on daily chemotherapy was better with ondansetron on days 3 (80 vs 17%, p = 0.035) and 4 (90 vs 33%, p = 0.036). Furthermore, significantly more patients on ondansetron enjoyed normal food intake on day 1 (71 vs 14%, p = 0.000). Both antiemetic regimens were well tolerated. No extrapyramidal reactions were observed. More... »

PAGES

104-109

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/bf03257433

DOI

http://dx.doi.org/10.1007/bf03257433

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1008309397


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Division of Haematology/Oncology, Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong", 
          "id": "http://www.grid.ac/institutes/grid.194645.b", 
          "name": [
            "Division of Haematology/Oncology, Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chiu", 
        "givenName": "Edmond K. W.", 
        "id": "sg:person.016204300724.55", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016204300724.55"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Haematology/Oncology, Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong", 
          "id": "http://www.grid.ac/institutes/grid.194645.b", 
          "name": [
            "Division of Haematology/Oncology, Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Liang", 
        "givenName": "Raymond", 
        "id": "sg:person.07707430152.30", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07707430152.30"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Haematology/Oncology, Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong", 
          "id": "http://www.grid.ac/institutes/grid.194645.b", 
          "name": [
            "Division of Haematology/Oncology, Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lie", 
        "givenName": "Albert", 
        "id": "sg:person.010762116764.18", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010762116764.18"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Haematology/Oncology, Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong", 
          "id": "http://www.grid.ac/institutes/grid.194645.b", 
          "name": [
            "Division of Haematology/Oncology, Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Todd", 
        "givenName": "David", 
        "id": "sg:person.01253327276.51", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01253327276.51"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Haematology/Oncology, Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong", 
          "id": "http://www.grid.ac/institutes/grid.194645.b", 
          "name": [
            "Division of Haematology/Oncology, Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chan", 
        "givenName": "T. K.", 
        "id": "sg:person.01062516260.15", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01062516260.15"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.2165/00003495-198300251-00007", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007445653", 
          "https://doi.org/10.2165/00003495-198300251-00007"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.1987.177", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007214275", 
          "https://doi.org/10.1038/bjc.1987.177"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00292884", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048304411", 
          "https://doi.org/10.1007/bf00292884"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1994-08", 
    "datePublishedReg": "1994-08-01", 
    "description": "Ondansetron was compared with conventional-dose metoclopramide in a randomised trial for emesis control in 56 patients with lymphoma and leukaemia receiving commonly used chemotherapeutic regimens that are moderately emetogenic. Emetogenic chemotherapeutic agents were administered on day 1 to lymphoma patients and on days 1 to 5 to leukaemia patients. Ondansetron was superior to metoclopramide in the complete control of acute emesis (75 vs 43%, p = 0.03). Control of delayed emesis in lymphoma patients was marginally better with ondansetron on days 2 (89 vs 64%, p = 0.140) and 3 (94 vs 68%, p = 0.054). Continuous control of emesis for leukaemia patients on daily chemotherapy was better with ondansetron on days 3 (80 vs 17%, p = 0.035) and 4 (90 vs 33%, p = 0.036). Furthermore, significantly more patients on ondansetron enjoyed normal food intake on day 1 (71 vs 14%, p = 0.000). Both antiemetic regimens were well tolerated. No extrapyramidal reactions were observed.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/bf03257433", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1100199", 
        "issn": [
          "1173-2563", 
          "1179-1918"
        ], 
        "name": "Clinical Drug Investigation", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "8"
      }
    ], 
    "keywords": [
      "leukemia patients", 
      "day 1", 
      "emetogenic chemotherapeutic agents", 
      "Comparison of ondansetron", 
      "control of emesis", 
      "Moderately Emetogenic Chemotherapy", 
      "normal food intake", 
      "acute emesis", 
      "antiemetic regimens", 
      "extrapyramidal reactions", 
      "emetogenic chemotherapy", 
      "emesis control", 
      "more patients", 
      "daily chemotherapy", 
      "chemotherapeutic regimens", 
      "lymphoma patients", 
      "food intake", 
      "ondansetron", 
      "patients", 
      "emesis", 
      "day 2", 
      "day 3", 
      "chemotherapeutic agents", 
      "regimens", 
      "chemotherapy", 
      "metoclopramide", 
      "lymphoma", 
      "control", 
      "leukemia", 
      "intake", 
      "trials", 
      "complete control", 
      "agents", 
      "comparison", 
      "reaction", 
      "continuous control"
    ], 
    "name": "Comparison of Ondansetron with Metoclopramide in the Control of Emesis Induced by Moderately Emetogenic Chemotherapy Used for Lymphoma and Leukaemia Patients", 
    "pagination": "104-109", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1008309397"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/bf03257433"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/bf03257433", 
      "https://app.dimensions.ai/details/publication/pub.1008309397"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-11-24T20:46", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221124/entities/gbq_results/article/article_237.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/bf03257433"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/bf03257433'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/bf03257433'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/bf03257433'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/bf03257433'


 

This table displays all metadata directly associated to this object as RDF triples.

133 TRIPLES      21 PREDICATES      64 URIs      53 LITERALS      6 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/bf03257433 schema:about anzsrc-for:11
2 anzsrc-for:1112
3 schema:author N136f126bcd2e4365b507151c32af3d9b
4 schema:citation sg:pub.10.1007/bf00292884
5 sg:pub.10.1038/bjc.1987.177
6 sg:pub.10.2165/00003495-198300251-00007
7 schema:datePublished 1994-08
8 schema:datePublishedReg 1994-08-01
9 schema:description Ondansetron was compared with conventional-dose metoclopramide in a randomised trial for emesis control in 56 patients with lymphoma and leukaemia receiving commonly used chemotherapeutic regimens that are moderately emetogenic. Emetogenic chemotherapeutic agents were administered on day 1 to lymphoma patients and on days 1 to 5 to leukaemia patients. Ondansetron was superior to metoclopramide in the complete control of acute emesis (75 vs 43%, p = 0.03). Control of delayed emesis in lymphoma patients was marginally better with ondansetron on days 2 (89 vs 64%, p = 0.140) and 3 (94 vs 68%, p = 0.054). Continuous control of emesis for leukaemia patients on daily chemotherapy was better with ondansetron on days 3 (80 vs 17%, p = 0.035) and 4 (90 vs 33%, p = 0.036). Furthermore, significantly more patients on ondansetron enjoyed normal food intake on day 1 (71 vs 14%, p = 0.000). Both antiemetic regimens were well tolerated. No extrapyramidal reactions were observed.
10 schema:genre article
11 schema:isAccessibleForFree false
12 schema:isPartOf N745e9d61a9b1488ca2de66359eb1ae03
13 Nbd9d106b49fb42f8a8e8d0c3e7ac1221
14 sg:journal.1100199
15 schema:keywords Comparison of ondansetron
16 Moderately Emetogenic Chemotherapy
17 acute emesis
18 agents
19 antiemetic regimens
20 chemotherapeutic agents
21 chemotherapeutic regimens
22 chemotherapy
23 comparison
24 complete control
25 continuous control
26 control
27 control of emesis
28 daily chemotherapy
29 day 1
30 day 2
31 day 3
32 emesis
33 emesis control
34 emetogenic chemotherapeutic agents
35 emetogenic chemotherapy
36 extrapyramidal reactions
37 food intake
38 intake
39 leukemia
40 leukemia patients
41 lymphoma
42 lymphoma patients
43 metoclopramide
44 more patients
45 normal food intake
46 ondansetron
47 patients
48 reaction
49 regimens
50 trials
51 schema:name Comparison of Ondansetron with Metoclopramide in the Control of Emesis Induced by Moderately Emetogenic Chemotherapy Used for Lymphoma and Leukaemia Patients
52 schema:pagination 104-109
53 schema:productId N185e5dc45ac549aabc5dd6ba8dcdef94
54 N2da412a9c1704d37a8eef85d6cfb1a97
55 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008309397
56 https://doi.org/10.1007/bf03257433
57 schema:sdDatePublished 2022-11-24T20:46
58 schema:sdLicense https://scigraph.springernature.com/explorer/license/
59 schema:sdPublisher N01495257f9c745509416350ab292227a
60 schema:url https://doi.org/10.1007/bf03257433
61 sgo:license sg:explorer/license/
62 sgo:sdDataset articles
63 rdf:type schema:ScholarlyArticle
64 N01495257f9c745509416350ab292227a schema:name Springer Nature - SN SciGraph project
65 rdf:type schema:Organization
66 N136f126bcd2e4365b507151c32af3d9b rdf:first sg:person.016204300724.55
67 rdf:rest Nfcd6446960ef465d97346c8ce0e15d83
68 N185e5dc45ac549aabc5dd6ba8dcdef94 schema:name doi
69 schema:value 10.1007/bf03257433
70 rdf:type schema:PropertyValue
71 N2da412a9c1704d37a8eef85d6cfb1a97 schema:name dimensions_id
72 schema:value pub.1008309397
73 rdf:type schema:PropertyValue
74 N560b0b46422148ecb8ba769722cd154e rdf:first sg:person.01062516260.15
75 rdf:rest rdf:nil
76 N745e9d61a9b1488ca2de66359eb1ae03 schema:issueNumber 2
77 rdf:type schema:PublicationIssue
78 N87c7c8201b904b649585cf0892b2a81b rdf:first sg:person.010762116764.18
79 rdf:rest N9c667d0140b24169bbb7ea71b3274399
80 N9c667d0140b24169bbb7ea71b3274399 rdf:first sg:person.01253327276.51
81 rdf:rest N560b0b46422148ecb8ba769722cd154e
82 Nbd9d106b49fb42f8a8e8d0c3e7ac1221 schema:volumeNumber 8
83 rdf:type schema:PublicationVolume
84 Nfcd6446960ef465d97346c8ce0e15d83 rdf:first sg:person.07707430152.30
85 rdf:rest N87c7c8201b904b649585cf0892b2a81b
86 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
87 schema:name Medical and Health Sciences
88 rdf:type schema:DefinedTerm
89 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
90 schema:name Oncology and Carcinogenesis
91 rdf:type schema:DefinedTerm
92 sg:journal.1100199 schema:issn 1173-2563
93 1179-1918
94 schema:name Clinical Drug Investigation
95 schema:publisher Springer Nature
96 rdf:type schema:Periodical
97 sg:person.01062516260.15 schema:affiliation grid-institutes:grid.194645.b
98 schema:familyName Chan
99 schema:givenName T. K.
100 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01062516260.15
101 rdf:type schema:Person
102 sg:person.010762116764.18 schema:affiliation grid-institutes:grid.194645.b
103 schema:familyName Lie
104 schema:givenName Albert
105 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010762116764.18
106 rdf:type schema:Person
107 sg:person.01253327276.51 schema:affiliation grid-institutes:grid.194645.b
108 schema:familyName Todd
109 schema:givenName David
110 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01253327276.51
111 rdf:type schema:Person
112 sg:person.016204300724.55 schema:affiliation grid-institutes:grid.194645.b
113 schema:familyName Chiu
114 schema:givenName Edmond K. W.
115 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016204300724.55
116 rdf:type schema:Person
117 sg:person.07707430152.30 schema:affiliation grid-institutes:grid.194645.b
118 schema:familyName Liang
119 schema:givenName Raymond
120 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07707430152.30
121 rdf:type schema:Person
122 sg:pub.10.1007/bf00292884 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048304411
123 https://doi.org/10.1007/bf00292884
124 rdf:type schema:CreativeWork
125 sg:pub.10.1038/bjc.1987.177 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007214275
126 https://doi.org/10.1038/bjc.1987.177
127 rdf:type schema:CreativeWork
128 sg:pub.10.2165/00003495-198300251-00007 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007445653
129 https://doi.org/10.2165/00003495-198300251-00007
130 rdf:type schema:CreativeWork
131 grid-institutes:grid.194645.b schema:alternateName Division of Haematology/Oncology, Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong
132 schema:name Division of Haematology/Oncology, Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong
133 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...